José Guilherme Datorre

Ms. José Guilherme Datorre

Barretos Cancer Hospital
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
ACAna Carolina de Carvalho
Ana Carolina de Carvalho
LPLeandro de Mattos Pereira
Leandro de Mattos Pereira
JDJosé Guilherme Datorre
José Guilherme Datorre
WSWellington dos Santos
Wellington dos Santos
GBGustavo Noriz Berardinelli
Gustavo Noriz Berardinelli
RRRui M. Reis
Rui M. Reis
Microbial diversity has been pointed out as a major factor in the development and progression of colorectal cancer (CRC). We sought to explore the richness and abundance of the microbial community of a series of colorectal tumor samples treated at Barretos Cancer Hospital, Brazil, through 16S rRNA sequencing. The presence and the impact of Fusobacterium nucleatum (Fn) DNA in CRC prognosis was further evaluated by qPCR in a series of 152 CRC cases. An enrichment for potentially oncogenic bacteria in CRC was observed, with Fusobacterium being the most abundant genus in the tumor tissue. In the validation dataset, Fn was detected in 35/152 (23.0%) of fresh-frozen tumor samples and in 6/57 (10.5%) of paired normal adjacent tissue, with higher levels in the tumor (p = 0.0033). Fn DNA in the tumor tissue was significantly associated with proximal tumors (p = 0.001), higher depth of invasion (p = 0.014), higher clinical stages (p = 0.033), poor differentiation (p = 0.011), MSI-positive status (p < 0.0001), BRAF mutated tumors (p < 0.0001), and the loss of expression of mismatch-repair proteins MLH1 (p < 0.0001), MSH2 (p = 0.003), and PMS2 (p < 0.0001). Moreover, the presence of Fn DNA in CRC tissue was also associated with a worse patient cancer-specific survival (69.9 vs. 82.2% in 5 years; p = 0.028) and overall survival (63.5 vs. 76.5%; p = 0.037). Here we report, for the first time, the association of F. nucleatum presence with important clinical and molecular features in a Brazilian cohort of CRC patients. Tumor detection and classification based on the gut microbiome might provide a promising approach to improve the prediction of patient outcome.

8 December 2020 in Pathobiology
Verified
Journal Article
Open access
PDF file
JDJosé Guilherme Datorre
José Guilherme Datorre
ACAna Carolina de Carvalho
Ana Carolina de Carvalho
DGDenise Peixoto Guimarães
Denise Peixoto Guimarães
RRRui M. Reis
Rui M. Reis
Colorectal cancer (CRC) is one of the most frequent and deadly neoplasms worldwide. Genetic factors, lifestyle habits, and inflammation are important risk factors associated with CRC development. In recent years, growing evidence has supporting the significant role of the intestinal microbiome in CRC carcinogenesis. Disturbances in the healthy microbial balance, known as dysbiosis, are frequently observed in these patients. Pathogenic microorganisms that induce intestinal dysbiosis have become an important target to determine the role of bacterial infection in tumorigenesis. Interestingly, the presence of different bacterial strains, such as Fusobacterium nucleatum, has been detected in tissue and stool from patients with CRC and associated with substantial clinical and molecular features, as well as with patient therapy response. Therefore, understanding how the presence and levels of F. nucleatumstrains in the gut affect the risk of CRC onset and progression may inform suitable candidates for interventions focused on modulation of this bacteria. Here we review new insights into the role of gut microbiota in CRC carcinogenesis and the clinical utility of using the detection of F. nucleatum in different settings such as screening, prognosis, and microbiota modulation as a means to prevent cancer, augment therapies, and reduce adverse effects of treatment.

5 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
JDJosé Guilherme Datorre
José Guilherme Datorre
ACAna Carolina de Carvalho
Ana Carolina de Carvalho
MRMariana Bisarro dos Reis
Mariana Bisarro dos Reis
MRMonise dos Reis
Monise dos Reis
MMMarcus Matsushita
Marcus Matsushita
RRRui M. Reis
Rui M. Reis
The use of droplet digital PCR (ddPCR) to identify and quantify low-abundance targets is a significant advantage for accurately detecting potentially oncogenic bacteria. Fusobacterium nucleatum (Fn) is implicated in colorectal cancer (CRC) tumorigenesis and is becoming an important prognostic biomarker. We evaluated the detection accuracy and clinical relevance of Fn DNA by ddPCR in a molecularly characterized, formalin-fixed, paraffin-embedded (FFPE) CRC cohort previously analyzed by qPCR for Fn levels. Following a ddPCR assay optimization and an analytical evaluation, Fn DNA were measured in 139 CRC FFPE cases. The measures of accuracy for Fn status compared to the prior results generated by qPCR and the association with clinicopathological and molecular patients’ features were also evaluated. The ddPCR-based Fn assay was sensitive and specific to positive controls. Fn DNA were detected in 20.1% of cases and further classified as Fn-high and Fn-low/negative, according to the median amount of Fn DNA that were detected in all cases and associated with the patient’s worst prognosis. There was a low agreement between the Fn status determined by ddPCR and qPCR (Cohen’s Kappa = 0.210). Our findings show that ddPCR can detect and quantify Fn in FFPE tumor tissues and highlights its clinical relevance in Fn detection in a routine CRC setting.

4 August 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
HJHoward Lopes Ribeiro Junior
Howard Lopes Ribeiro Junior
LNLázaro Antônio Campanha Novaes
Lázaro Antônio Campanha Novaes
JDJosé Guilherme Datorre
José Guilherme Datorre
DMDaniel Antunes Moreno
Daniel Antunes Moreno
RRRui M. Reis
Rui M. Reis
The development of new screening methods and diagnostic tests for traits, common diseases, and cancer is linked to the advent of precision genomic medicine, in which health care is individually adjusted based on a person’s lifestyle, environmental influences, and genetic variants. Based on genome-wide association study (GWAS) analysis, rapid and continuing progress in the discovery of relevant single nucleotide polymorphisms (SNPs) for traits or complex diseases has increased interest in the potential application of genetic risk models for routine health practice. The polygenic risk score (PRS) estimates an individual’s genetic risk of a trait or disease, calculated by employing a weighted sum of allele counts combined with non-genetic variables. However, 98.38% of PRS records held in public databases relate to the European population. Therefore, PRSs for multiethnic populations are urgently needed. We performed a systematic review to discuss the role of polygenic risk scores in advancing precision medicine for different cancer types in multiethnic non-European populations.

2 July 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
JDJosé Guilherme Datorre
José Guilherme Datorre
MRMariana B. dos Reis
Mariana B. dos Reis
ACAna C. de Carvalho
Ana C. de Carvalho
JPJun Porto
Jun Porto
GRGabriela Helena Rodrigues
Gabriela Helena Rodrigues
RRRui M. Reis
Rui M. Reis
Fecal immunochemical test (FIT) followed by colonoscopy in positive cases is commonly used for population-based colorectal cancer screening. However, specificity of FIT for colorectal cancer is not ideal and has poor performance for advanced adenoma detection. Fecal Fusobacterium nucleatum (Fn) detection has been proposed as a potential noninvasive biomarker for colorectal cancer and advanced adenoma detection. We aimed to evaluate the diagnostic performance of Fn detection using droplet digital PCR (ddPCR) in FIT samples from individuals enrolled in a colorectal cancer screening program with colorectal adenoma or cancer. We evaluated Fn presence in DNA isolated from FIT leftover material of 300 participants in a colorectal cancer screening program using ddPCR. The Fn DNA amount was classified as Fn-low/negative and Fn-high, and the association with patients’ clinicopathological features and accuracy measurements was calculated. Fn-high levels were more prevalent in FIT-positive (47.2%, n = 34 of 72) than FIT-negative samples (28.9%, n = 66 of 228; P < 0.04). Among FIT-positive samples, high Fn levels were significantly more frequent in patients with cancer (CA, n = 8) when compared to normal (NT, n = 16; P = 0.02), non-advanced adenomas (NAA, n = 36; P = 0.01), and advanced adenomas (AA, n = 12; P = 0.01). Performance analysis of Fn in FIT-positive samples for colorectal cancer detection yielded an AUC of 0.8203 [confidence interval (CI), 0.6464–0.9942], with high sensitivity (100%) and specificity of 50%. Concluding, we showed the feasibility of detecting Fn in FIT leftovers using the ultrasensitive ddPCR technique. Furthermore, we highlighted the potential use of Fn levels in fecal samples to ameliorate colorectal cancer detection. Prevention Relevance: Fusobacterium nucleatum detection by droplet digital PCR could prioritize the selection of fecal immunochemical test–positive individuals who might benefit the most from the colonoscopy procedure.

14 April 2023 in Endoscopy
Verified
Journal Article
Closed access
DGD. Guimarães
D. Guimarães
JDJosé Guilherme Datorre
José Guilherme Datorre
MRM. B. Reis
M. B. Reis
MRM. Reis
M. Reis
ACA. Carvalho
A. Carvalho
RRRui M. Reis
Rui M. Reis
Aims Fecal immunochemical test (FIT) has been the most frequent method used in population-based CRC screening programs. Fecal Fusobacterium nucleatum (Fn) has been reported as a potential noninvasive biomarker for CRC and advanced adenoma detection. We aimed to evaluate the diagnostic performance of Fn by ddPCR in FIT samples. Methods Fn presence was evaluated by ddPCR in bacterial DNA isolated from FIT (fecal immunochemical test) samples. A total of 161 samples from positive and negative screeners from Barretos Cancer Hospital CRC Screening Program were analyzed. Results High Fn levels were found in 50% of FIT-positive samples (n=82), and 9.6% of FIT-negative (n=166) and Fn high levels were significantly prevalent in FIT samples from cancer patients compared to early adenoma (p=0.049) and with no lesion (p=0.031). Performance analysis of Fn in FIT samples from screeners to detect cancer showed an AUC of 0.956 (CI:0.805-1.000) with high sensitivity (100%) and specificity (88.3%). An AUC value of 0.675 (sensitivity of 71% and specificity of 55% for advanced adenoma) was shown. Conclusions This study shows the feasibility of detecting Fn in feces from FIT samples using an ultrasensitive ddPCR technique and highlights the potential of DNA testing for Fn in fecal samples to help CRC detection. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany